European marketing application for avt23, a proposed biosimilar to xolair® (omalizumab), accepted by the european medicines agency

London and reykjavik, iceland, oct. 06, 2025 (globe newswire) -- advanz pharma holdco limited (“advanz pharma”), a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe and alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the european medicines agency (ema) has accepted a marketing authorization application for avt23, a proposed biosimilar to xolair® (omalizumab).
ALVO Ratings Summary
ALVO Quant Ranking